Skip to content

Product Evaluation of a Newly Developed Intermittent Catheter.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02966015
Enrollment
153
Registered
2016-11-17
Start date
2016-05-31
Completion date
2016-06-30
Last updated
2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incontinence, Urinary

Brief summary

The aim of the study is to investigate the navigation of a newly developed catheter.

Interventions

This is a newly developed catheter

Sponsors

Coloplast A/S
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male and at least 18 years 2. Has used Intermittent self-catheterization at least 3 months 3. Has normal to slightly reduced hand mobility 4. Use catheter size CH12 or CH14 (must use same size during product evaluation)

Exclusion criteria

1. Currently receiving treatment for urinary tract infection 2. Currently receiving chemotherapy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Successfully Able to Insert Catheter1 weekThe subjects had to evaluate if it was possible to insert and navigate the Coloplast Test catheter through urethra by the 5-point Likert question: How did you find the catheter navigates through the urethra during insertion ( Very easily, Easily, Neither/nor, Difficultly, Very difficultly, Not possible). The catheterization was considered successful if it was possible to insert the catheter, meaning that ifthey selected any other answer than 'not possible'.

Participant flow

Participants by arm

ArmCount
Tiemann/Coudé Users
The Tiemann/Coudé users used the new Coloplast Test catheter for 1 week. At inclusion the subjects were introduced to the product. They were asked to perform catheterization with Coloplast Test catheter. Those who were able to catheterize and wished to participate were included in the 1 week trial. Coloplast test catheter: This is a newly developed catheter
95
Traditional Sleeve Catheter Users
The traditional sleeve catheter users used the new Coloplast Test catheter for 1 week. At inclusion the subjects were introduced to the product. They were asked to perform catheterization with Coloplast Test catheter. Those who were able to catheterize and wished to participate were included in the 1 week trial.
58
Total153

Withdrawals & dropouts

PeriodReasonFG000FG001
Inclusion Visitdid not answer questionnaire83

Baseline characteristics

CharacteristicTiemann/Coudé UsersTraditional Sleeve Catheter UsersTotal
Age, Customized
Participants older than 18 years
95 participants58 participants153 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
95 Participants58 Participants153 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 950 / 58
other
Total, other adverse events
0 / 950 / 58
serious
Total, serious adverse events
0 / 950 / 58

Outcome results

Primary

Number of Participants Successfully Able to Insert Catheter

The subjects had to evaluate if it was possible to insert and navigate the Coloplast Test catheter through urethra by the 5-point Likert question: How did you find the catheter navigates through the urethra during insertion ( Very easily, Easily, Neither/nor, Difficultly, Very difficultly, Not possible). The catheterization was considered successful if it was possible to insert the catheter, meaning that ifthey selected any other answer than 'not possible'.

Time frame: 1 week

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tiemann/Coudé UsersNumber of Participants Successfully Able to Insert Catheter82 Participants
Traditional Sleeve Catheter UsersNumber of Participants Successfully Able to Insert Catheter58 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026